Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 19
页数：3
相关论文
共 50 条
  • [1] Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Fraser, Graeme A. M.
    Chanan-Khan, Asher
    Demirkan, Fatih
    Santucci Silva, Rodrigo
    Grosicki, Sebastian
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy L.
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Samoilova, Olga
    Pavlovsky, Miguel A.
    Goy, Andre
    Mato, Anthony
    Hallek, Michael
    Salman, Mariya
    Tamegnon, Monelle
    Sun, Steven
    Connor, Anne
    Nottage, Kerri
    Schuier, Natasha
    Balasubramanian, Sriram
    Howes, Angela
    Cramer, Paula
    LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3188 - 3197
  • [2] Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Fraser, Graeme
    Chanan-Khan, Asher
    Demirkan, Faith
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Samoilova, Olga
    Pavlosky, Miguel
    Hallek, Michael
    Salman, Mariya
    Tamegnon, Monelle
    Sun, Steven
    Connor, Anne
    Nottage, Kerri
    Balasubramanian, Sriram
    Howes, Angela
    Cramer, Paula
    LEUKEMIA & LYMPHOMA, 2020, 61 : 106 - 108
  • [3] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    Fraser, G.
    Cramer, P.
    Demirkan, F.
    Silva, R. Santucci
    Grosicki, S.
    Pristupa, A.
    Janssens, A.
    Mayer, J.
    Bartlett, N. L.
    Dilhuydy, M-S
    Pylypenko, H.
    Loscertales, J.
    Avigdor, A.
    Rule, S.
    Villa, D.
    Samoilova, O.
    Panagiotidis, P.
    Goy, A.
    Pavlovsky, M. A.
    Karlsson, C.
    Hallek, M.
    Mahler, M.
    Salman, M.
    Sun, S.
    Phelps, C.
    Balasubramanian, S.
    Howes, A.
    Chanan-Khan, A.
    LEUKEMIA, 2019, 33 (04) : 969 - 980
  • [4] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    G. Fraser
    P. Cramer
    F. Demirkan
    R. Santucci Silva
    S. Grosicki
    A. Pristupa
    A. Janssens
    J. Mayer
    N. L. Bartlett
    M.-S. Dilhuydy
    H. Pylypenko
    J. Loscertales
    A. Avigdor
    S. Rule
    D. Villa
    O. Samoilova
    P. Panagiotidis
    A. Goy
    M. A. Pavlovsky
    C. Karlsson
    M. Hallek
    M. Mahler
    M. Salman
    S. Sun
    C. Phelps
    S. Balasubramanian
    A. Howes
    A. Chanan-Khan
    Leukemia, 2019, 33 : 969 - 980
  • [5] The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia
    Hallek, Michael
    Kay, Neil E.
    Osterborg, Anders
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Wan, Ying
    Sun, Steven
    Zhuang, Sen Hong
    Howes, Angela
    FUTURE ONCOLOGY, 2015, 11 (01) : 51 - 59
  • [6] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [7] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [8] Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
    Chanan-Khan, Asher
    Cramer, Paula
    Demirkan, Fatih
    Fraser, Graeme
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Bartlett, Nancy L.
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Mariya
    Howes, Angela
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [9] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
    Huang, Xiaojun
    Qiu, Lugui
    Jin, Jie
    Zhou, Daobin
    Chen, Xiequn
    Hou, Ming
    Hu, Jianda
    Hu, Yu
    Ke, Xiaoyan
    Li, Junmin
    Liang, Yingmin
    Liu, Ting
    Lv, Yue
    Ren, Hanyun
    Sun, Aining
    Wang, Jianmin
    Zhao, Chunting
    Salman, Mariya
    Sun, Steven
    Howes, Angela
    Wang, Jingzhao
    Wu, Peng
    Li, Jianyong
    CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055
  • [10] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
12345